Article Data

  • Views 599
  • Dowloads 109

Original Research

Open Access

Exploring biomarkers for uterine leiomyosarcoma via combination of iMDM algorithm and pathway enrichment analysis

  • Haiyang Jiang1,#
  • Luyun Qu1,#
  • Zenghui Li1
  • Xiaohong Li1
  • Jing Wang1
  • Jianqing Hou1,*,

1Department of Gynecology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University Medical College, Yantai, China

DOI: 10.12892/ejgo4335.2019 Vol.40,Issue 2,April 2019 pp.268-274

Accepted: 05 September 2017

Published: 10 April 2019

*Corresponding Author(s): Jianqing Hou E-mail: houjianqingyt@163.com

About author: #Co-first authors and equal contributors.

Abstract

Objective: To understand the pathogenesis and etiology of uterine leiomyosarcoma (ULMS) at its early age, as well as explore an effective method for the treatment of it. Materials and Methods: First of all, the gene expression profile data of ULMS and the protein-protein interaction (PPI) data were recruited and preprocessed. Then, the inference of multiple differential modules (iMDM) algorithm, which contained differential co-expression network (DCN) construction and identification of multiple differential modules (M-DMs) in DCN was introduced to identify candidate M-DMs. In the following, the M-DMs were identified via statistical analysis was conducted. Finally, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was conducted to disclose the function of these M-DMs. Results: A DCN consisting of 1656 nodes (4182 edges) was built, and 16 seed genes were exacted from the DCN by ranking the z-scores in descending order and setting the threshold value of the top 1%. After refinement, 12 candidate M-DMs were obtained and all of these M-DMs resulted to be M-DMs. The pathway enrichment analysis indicated that five modules were enriched in mRNA Splicing pathway, and three modules were enriched in Gene Expression pathway. The authors predicted that these two pathways and the 12 seed genes might play important roles during the process of the occurrence and development of ULMS. Conclusions: This method that was used in the present study to perform the analysis on ULMS was suitable. The authors predict that the results could offer investigators valuable resources for better understanding the underlying mechanisms ULMS on the gene level, and the results will give great insights to reveal pathological mechanism underlying this disease, or even provide a hand for future study of related disease research.

Keywords

Uterine leiomyosarcoma; Multiple differential modules; Protein-protein interaction network; Pathway; Biomarker

Cite and Share

Haiyang Jiang,Luyun Qu,Zenghui Li,Xiaohong Li,Jing Wang,Jianqing Hou. Exploring biomarkers for uterine leiomyosarcoma via combination of iMDM algorithm and pathway enrichment analysis. European Journal of Gynaecological Oncology. 2019. 40(2);268-274.

References

[1] Schwameis R., Grimm C., Petru E., Natter C., Staudigl C., Lamm W., et al.: “The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma”. PLoS One, 2014, 10, e0133838.

[2] Zivanovic O., Jacks L.M., Iasonos A., Jr M.M.L., Soslow R.A., Veras E., et al.: “A Nomogram to Predict Postresection 5-Year Overall Survival for Patients With Uterine Leiomyosarcoma”. Cancer, 2012, 118, 660.

[3] Hensley M.L., Wathen J.K., Maki R.G., Araujo D.M., Sutton G., Priebat D.A., et al.: “Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma : Results of a phase 2 trial (SARC 005)”. Can- cer, 2013, 119, 1555.

[4] Hoang H.L., Ensor K., Rosen G., Leon P.H., Raccuia J.S.: “Prognostic factors and survival in patients treated surgically for recurrent metastatic uterine leiomyosarcoma”. Int. J. Surg. Oncol., 2014, 2014, (919323.

[5] Yen M.S., Chen J.R., Wang P.H., Wen K.C., Chen Y.J., Ng H.T.: “Uterine sarcoma part III-Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review”. Taiwanese. J. Obstet. Gynecol., 2016, 55, 625.

[6] Amant F., Lorusso D., Mustea A., Duffaud F., Pautier P.: “Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin”. Sarcoma, 2015, 2015, 1.

[7] Davidson B., Abeler V.M., Førsund M., Holth A., Yang Y., Kobayashi Y., et al.: “Gene expression signatures of primary and metastatic uterine leiomyosarcoma”. Hum. Pathol., 2013, 45, 691.

[8] Difeo A., Sennet R., Huang F., Levine D., Kalir T., Rijn M.V.D., et al.: “KLF6SV1 is a novel uterine leiomyosarcoma gene: From transgenic mouse model to human disease”. Gynecol. Oncol., 2011, 120, S8.

[9] Mäkinen N., Aavikko M., Heikkinen T., Taipale M., Taipale J., Koivistokorander R., et al.: “Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12”. PLoS. Genet., 2016, 12, e1005850.

[10] Khater M.K., Shalaby S.M., Al-Hendy A.A.: “A highly specific molecular bioimaging approach for diagnosis of human uterine leiomyosarcoma”. Reprod. Sci., 2016, 23, 262A.

[11] Barlin J.N., Zhou Q.C., Leitao M.M., Bisogna M., Olvera N., Shih K.K., et al.: “Molecular Subtypes of Uterine Leiomyosarcoma and Correlation with Clinical Outcome 1 2”. Neoplasia, 2015, 17, 183.

[12] Zhang B., Tian Y., Jin L., Li H., Shih I.M., Madhavan S., et al.: “DDN: a caBIG® analytical tool for differential network analysis”. Bioinformatics, 2011, 27, 1036.

[13] Luscombe N.M., Babu M.M., Yu H., Snyder M., Teichmann S.A., Gerstein M.: “Genomic analysis of regulatory network dynamics reveals large topological changes”. Nature, 2004, 431, 308.

[14] Guénolé A., Srivas R., Vreeken K., Wang Z.Z., Wang S., Krogan N.J., et al.: “Dissection of DNA Damage Responses Using Multiconditional Genetic Interaction Maps”. Mol. Cell., 2013, 49, 346.

[15] Ellis J.D., Barrios-Rodiles M., Colak R., Irimia M., Kim T., Calarco J.A., et al.: “Tissue-specific alternative splicing remodels protein-protein interaction networks”. Mol. Cell., 2012, 46, 884.

[16] Ma L., Robinson L.N., Towle H.C.: “ChREBP• Mlx Is the Principal Mediator of Glucose-induced Gene Expression in the Liver”. J. Biol. Chem., 2006, 281, 28721.

[17] Rifai N., Ridker P.M.: “Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening”. Clin. Chem., 2001, 47, 28.

[18] Pepper S.D., Saunders E.K., Edwards L.E., Wilson C.L., Miller C.J.: “The utility of MAS5 expression summary and detection call algorithms”. BMC Bioinformatics, 2007, 8, 273.

[19] Benesty J., Chen J., Huang Y., Cohen I.: “Pearson correlation coefficient”. In: Cohen I., Huang Y., Chen J., Benesty J. (eds). Noise reduction in speech processing. Heidelberg: Springer, 2009, 1.

[20] Robinson M.D., McCarthy D.J., Smyth G.K.: “edgeR: a Bioconductor package for differential expression analysis of digital gene expression data”. Bioinformatics, 2010, 26, 139.

[21] Ma X., Gao L., Tan K.: “Modeling disease progression using dynamics of pathway connectivity”. Bioinformatics, 2014, 30, 2343.

[22] Benjamini Y., Hochberg Y.: “Controlling the false discovery rate: a practical and powerful approach to multiple testing”. J. R. Stat. Soc. Series. B. Stat. Methodol., 1995, 57, 289.

[23] Routledge R.: “Fisher's exact test”. In: Encyclopedia of Biostatistics. Wiley Online Library: John Wiley & Sons, Ltd., 2005

[24] Haynes W.: “Benjamini–Hochberg Method”. In: Encyclopedia of Systems Biology. Dordrecht, The Netherlands: Springer: 2013, 78.

[25] Hayashi T., Kawano M., Ichimura T., Ida K., Ando H., Zharhary D., et al.: “Molecular Pathology and Novel Clinical Therapy for Uterine Leiomyosarcoma”. Ant. Res., 2016, 36, 4997.

[26] Wu T.I., Chang T.C., Hsueh S., Hsu K.H., Chou H.H., Huang H.J., et al.: “Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma”. Gynecol. Oncol., 2006, 100, 166.

[27] Davidson B., Abeler V.M., Førsund M., Holth A., Yang Y., Kobayashi Y., et al.: “Gene expression signatures of primary and metastatic uterine leiomyosarcoma”. Hum. Pathol., 2014, 45, 691.

[28] Barlin J.N., Zhou Q.C., Leitao M.M., Bisogna M., Olvera N., Shih K.K., et al.: “Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcome”. Neoplasia, 2015, 17, 183.

[29] Hayashi T., Faustman D.L.: “Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice”. Can. Res., 2002, 62, 24.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top